Concepedia

INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR RETINOPATHY OF PREMATURITY

San-Ni Chen, Ie‐Bin Lian, Ya-Chi Hwang, Yi‐Hsing Chen, Yao-Chung Chang, Kun‐Mu Lee, Chih-Chun Chuang, Wei‐Chi Wu

Retina · 2014 · 121 citations · 38 references

DOI

Abstract

Both bevacizumab and ranibizumab showed similar efficacy in the regression of ROP with minor mean refractive errors at 1 year of corrected age. However, high myopia was more prevalent in the bevacizumab-treated eyes.

References

38

Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration

New England Journal of Medicine · 2011 · 2.6K citations · Full text

Revised Indications for the Treatment of Retinopathy of Prematurity

Archives of Ophthalmology · 2003 · 1.6K citations

Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity

Helen A. Mintz-Hittner, Kathleen A. Kennedy, Alice Z. Chuang · New England Journal of Medicine · 2011 · 1.4K citations · Full text

Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation

Georg Breier, Ursula Albrecht, S. Sterrer et al. · Development · 1992 · 1.1K citations · Full text

, , +17

Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration

Usha Chakravarthy, Simon Harding, Chris Rogers et al. · Ophthalmology · 2012 · 771 citations

, , +3